Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions.
Pharmacogenomics
; 25(1): 5-19, 2024 Jan.
Article
em En
| MEDLINE
| ID: mdl-38230622
ABSTRACT
Aim:
Implementation of CYP2C19 point-of-care (POC) pharmacogenetic (PGx) testing with personalized treatment recommendations.Methods:
POC CYP2C19 genotyping plus expert evaluation of risk factors for ischemic and bleeding events.Results:
167 patients underwent PGx testing, 54 (32.3%) were CYP2C19 loss of function carriers, and POC versus standard PGx analysis results for *2 and *3 variants matched in 100%. Antiplatelet therapy was adjusted in 44 patients (26.3%), but always required consideration of patient-specific factors.Conclusion:
CYP2C19 POC-PGx is reliable and offers clinically relevant advantages for immediate evidence-based adaptations of antiplatelet therapy, whereas in less acute cases conventional PGx testing can also have advantages. Antiplatelet therapy has become more complex, and implementation of PGx-based personalized antiplatelet therapy requires complementary expert knowledge.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Inibidores da Agregação Plaquetária
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article